Wanbin Zhang received his B.S. and M.S. from East China University of Science and Technology (ECUST) in 1985 and 1988, respectively. He earned his Ph.D. at Osaka University in 1997 under the supervision of Prof. Isoo Ikeda. Following his Ph.D., he remained at Osaka University as an Assistant Professor until 2001, after which he continued his career as a Research Fellow at Mitsubishi Chemical Corporation in 2003. Since 2003, he has been a professor in the School of Chemistry and Chemical Engineering at Shanghai Jiao Tong University (SJTU). He was promoted to Distinguished Professor in 2013 and subsequently appointed as Chair Professor in 2021, followed by the K. C. Wong Chair Professor in 2025. He has been appointed as Director of Shanghai key laboratory for Molecular Engineering of Chiral Drugs since 2017. He has long been engaged in fundamental and applied research in the field of asymmetric catalysis. He has published more than 300 research papers in internationally peer-reviewed journals including Science, Nat. Chem., J. Am. Chem. Soc., Angew. Chem.; with over 70 patents granted in China and abroad. Several asymmetric catalytic technologies derived from his discoveries have already been applied in industry. He was elected as an Academician of the Chinese Academy of Sciences, a Fellow of the Chinese Chemical Society, National High-Level Talent Special Support Programs (10,000 Talents Program) - Distinguished Teacher, and a Shanghai Model Worker. He received the National Natural Science Award (2nd class, 2023), the first class prize of the China Industry-University-Research Cooperation Innovation Achievement Award (2022), and the Baosteel Outstanding Teacher Special Prize (2024).
## 讲座简介
暂无摘要
We have focused on asymmetric catalysis from the viewpoint of activity and selectivity for more than 20 years and developed a series of novel chiral ligands or catalysts and highly efficient asymmetric catalytic systems based on angle control and synergistic promotion strategies, respectively. The research achievements included: 1) the development of novel chiral bicyclic imidazole organocatalysts, which were applied for the first example of the catalytic asymmetric synthesis of P-stereogenic phosphoric acid derivatives; 2) the development of several novel bimetallic catalytic systems, which were applied for the first example of stereodivergent dual catalysis involving two metal catalysts; 3) the synergistic catalytic effect of CH···HC weak attractive interactions between the chiral ligand and the substrate was found to be crucial for reactivity and stereocontrol in rare or earth-abundant metal-catalyzed asymmetric hydrogenation. Importantly, key technological breakthroughs have been achieved for the industrial synthesis of several important chiral compounds, such as the fragrance including Menthol, Carvone and Camphorenal, antimalarial drug Artemisinin, anti-tuberculosis drug Bedaquiline, anti-epileptic drug Brivaracetam, and antiviral drug Remdesivir. Subsequent, the first production line of Menthol with an annual output of ten thousand tons in China has been built by Wanhua Chemical Group Co., Ltd and the first asymmetric catalytic production line of bedaquiline and brivaracetam in the world has been built by Aurisco and Aurisco Pharmaceutical. In addition, Wanxiang Technology Co., Ltd. has built a production line with an annual output of >3,000 tons including (R)-Carvone, Carvacro, Campholenic aldehyde, Brahmanol etc.
